Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Conference News ESC 2025

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Yael L. Maxwell

September 09, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Caitlin E. Cox

February 03, 2025

News Daily News

Top Coronary Artery Disease News of 2022

Yael L. Maxwell

December 29, 2022

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

News Conference News AHA 2020

SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults

Shelley Wood

November 13, 2020

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Poor Prescription Adherence After Acute MI Continues to Vex Researchers

L.A. McKeown

June 30, 2017

News Daily News

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

Michael O'Riordan

August 16, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Caitlin E. Cox

October 27, 2015

News Daily News

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

Caitlin E. Cox

October 27, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

Advertisement

CVD Still the Leading Cause of Death and Disease Globally

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

FDA Approves Triple Therapy Polypill for High Blood Pressure

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Top Coronary Artery Disease News of 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Poor Prescription Adherence After Acute MI Continues to Vex Researchers

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content